scholarly journals MCM2 and MCM5 as Prognostic Markers in Colon Cancer: A Worthwhile Approach

2008 ◽  
Vol 54 (2) ◽  
pp. 197-198 ◽  
Author(s):  
Maximilian Burger
Keyword(s):  
Colon Cancer ◽  
Prognostic Markers

CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer

2019 ◽  
Vol 90 ◽  
pp. 70-79
Author(s):  
Matthew J. Cecchini ◽  
Joanna C. Walsh ◽  
Jeremy Parfitt ◽  
Subrata Chakrabarti ◽  
Rohann J. Correa ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Markers ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

scholarly journals MicroRNAs Associated With Colon Cancer: New Potential Prognostic Markers and Targets for Therapy

2020 ◽  
Vol 8 ◽  
Author(s):  
Junfeng Zhu ◽  
Ying Xu ◽  
Shanshan Liu ◽  
Li Qiao ◽  
Jianqiang Sun ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Markers

scholarly journals Changes and Prognostic Value of lncRNA CASC9 in Patients with Advanced Colon Cancer after Chemotherapy

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Yingwei Jiao ◽  
Qiang Liu ◽  
Hongbo Zhao ◽  
Xianzhen Hu ◽  
Jinlong Sun ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Markers ◽  
Clinical Stage ◽  
Progression Free Survival ◽  
Pcr Assay ◽  
Clinical Value ◽  
Free Survival ◽  
Real Time Quantitative Pcr ◽  
Advanced Colon Cancer ◽  
Before And After

Objective. Colon cancer (CC) shows a gradual increasing incidence in recent years, and chemotherapy is a frequently adopted treatment for patients with middle or advanced colon cancer (ACC), but it lacks prognostic markers after CC. Methods. The changes of lncRNA CASC9 in 58 patients with CC were determined using a real-time quantitative PCR (qRT-PCR) assay before and after chemotherapy, and the correlation of serum lncRNA CASC9 with efficacy of FOLFOX4 regimen (oxaliplatin + calcium folinate + fluorouracil) was analyzed. The patients were followed up to understand the association of lncRNA CASC9 with overall survival (OS) and progression-free survival (PFS). Results. Patients with CC showed notably higher lncRNA CASC9 expression than controls, and lncRNA CASC9 presented an association with the clinical stage of the patients. In addition, lncRNA CASC9 demonstrated a clinical value in predicting efficacy on patients and acted as one independent prognostic factor for PFS in patients with ACC. Conclusions. With increased expression of serum lncRNA CASC9, patients with ACC suffered an unfavorable chemotherapy effect. In addition, serum lncRNA CASC9 is a promising sensitive indicator for prediction of ACC and is related to the clinical efficacy and prognosis of patients.

scholarly journals Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Fee Klupp ◽  
Lena Neumann ◽  
Christoph Kahlert ◽  
Johannes Diers ◽  
Niels Halama ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Prognostic Markers

Prognostic Markers in Colon Cancer

2012 ◽  
pp. 131-162
Author(s):  
Janine M. Davies ◽  
Howard L. McLeod
Keyword(s):  
Colon Cancer ◽  
Prognostic Markers

Prognostic markers for metastatic colon cancer patients undergoing multiple metastasectomies

2015 ◽  
Vol 26 (5) ◽  
pp. 386-391 ◽  
Author(s):  
Bala Basak Öven Ustaalioglu ◽  
Metin Tilki ◽  
Zeynep Gamze Kilicoglu ◽  
Ahmet Bilici ◽  
Ali Sürmelioglu
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Prognostic Markers ◽  
Metastatic Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document